Literature DB >> 24096737

Primary 4T1 tumor resection provides critical "window of opportunity" for immunotherapy.

Anahit Ghochikyan1, Arpine Davtyan, Armine Hovakimyan, Hayk Davtyan, Anna Poghosyan, Alexander Bagaev, Ravshan I Ataullakhanov, Edward L Nelson, Michael G Agadjanyan.   

Abstract

It is believed that primary tumor resection modulates host-tumor immune interaction, but this has not been characterized in a stringent breast cancer tumor model. This report, using the 4T1 murine mammary tumor model, characterizes for the first time the dynamic longitudinal changes in immunosuppressive and effector components of the immune system after resection of an established orthotopic primary tumor with a defined natural history of developing lung metastases. More specifically, we analyzed changes of absolute numbers and frequencies of MDSC, regulatory T cells (Treg), as well as activated CD4 and CD8 positive T cells in spleens and, in some studies, lungs of 4T1 tumor-bearing mice and mice after primary tumor resection. Importantly, using mathematical analyses we established that primary resection of an orthotopic tumor had created a "window of opportunity" with decreased tumor-associated immune suppression that existed for approximately 10 days. Although tumor resection did slightly prolong survival, it did not affect the ultimate development of metastatic disease since animals with resected tumors or intact primary tumors eventually died by day 47 and 43, respectively. This window of opportunity likely occurs in humans providing a rationale and parameters for integration and testing of immunotherapeutic strategies in this critical "window of opportunity" to combat the development of metastatic disease.

Entities:  

Mesh:

Year:  2013        PMID: 24096737      PMCID: PMC3946940          DOI: 10.1007/s10585-013-9619-0

Source DB:  PubMed          Journal:  Clin Exp Metastasis        ISSN: 0262-0898            Impact factor:   5.150


  46 in total

1.  Selective events in the metastatic process defined by analysis of the sequential dissemination of subpopulations of a mouse mammary tumor.

Authors:  C J Aslakson; F R Miller
Journal:  Cancer Res       Date:  1992-03-15       Impact factor: 12.701

2.  Cancer vaccines: pessimism in check.

Authors:  John M Timmerman; Ronald Levy
Journal:  Nat Med       Date:  2004-12       Impact factor: 53.440

3.  Deficiency in surface expression of E-selectin ligand promotes lung colonization in a mouse model of breast cancer.

Authors:  Behjatolah Monzavi-Karbassi; Tracy L Whitehead; Fariba Jousheghany; Cecile Artaud; Leah Hennings; Saeid Shaaf; Aubrey Slaughter; Soheila Korourian; Thomas Kelly; Magdalena Blaszczyk-Thurin; Thomas Kieber-Emmons
Journal:  Int J Cancer       Date:  2005-11-10       Impact factor: 7.396

4.  Reduction of myeloid-derived suppressor cells and induction of M1 macrophages facilitate the rejection of established metastatic disease.

Authors:  Pratima Sinha; Virginia K Clements; Suzanne Ostrand-Rosenberg
Journal:  J Immunol       Date:  2005-01-15       Impact factor: 5.422

5.  A novel orthotopic model of breast cancer metastasis to bone.

Authors:  M Lelekakis; J M Moseley; T J Martin; D Hards; E Williams; P Ho; D Lowen; J Javni; F R Miller; J Slavin; R L Anderson
Journal:  Clin Exp Metastasis       Date:  1999-03       Impact factor: 5.150

6.  Antitumor efficacy of DNA vaccination to the epigenetically acting tumor promoting transcription factor BORIS and CD80 molecular adjuvant.

Authors:  Dmitri Loukinov; Anahit Ghochikyan; Mikayel Mkrtichyan; Thomas E Ichim; Victor V Lobanenkov; David H Cribbs; Michael G Agadjanyan
Journal:  J Cell Biochem       Date:  2006-08-01       Impact factor: 4.429

7.  Reduction of established spontaneous mammary carcinoma metastases following immunotherapy with major histocompatibility complex class II and B7.1 cell-based tumor vaccines.

Authors:  B A Pulaski; S Ostrand-Rosenberg
Journal:  Cancer Res       Date:  1998-04-01       Impact factor: 12.701

8.  Regulatory T cells prevent CD8 T cell maturation by inhibiting CD4 Th cells at tumor sites.

Authors:  Nathalie Chaput; Guillaume Darrasse-Jèze; Anne-Sophie Bergot; Corinne Cordier; Stacie Ngo-Abdalla; David Klatzmann; Orly Azogui
Journal:  J Immunol       Date:  2007-10-15       Impact factor: 5.422

9.  Reduced inflammation in the tumor microenvironment delays the accumulation of myeloid-derived suppressor cells and limits tumor progression.

Authors:  Stephanie K Bunt; Linglin Yang; Pratima Sinha; Virginia K Clements; Jeff Leips; Suzanne Ostrand-Rosenberg
Journal:  Cancer Res       Date:  2007-10-15       Impact factor: 12.701

10.  Abnormal T regulatory cells (Tregs: FOXP3+, CTLA-4+), myeloid-derived suppressor cells (MDSCs: monocytic, granulocytic) and polarised T helper cell profiles (Th1, Th2, Th17) in women with large and locally advanced breast cancers undergoing neoadjuvant chemotherapy (NAC) and surgery: failure of abolition of abnormal treg profile with treatment and correlation of treg levels with pathological response to NAC.

Authors:  Chandan Verma; Jennifer M Eremin; Adrian Robins; Andrew J Bennett; Gerard P Cowley; Mohamed A El-Sheemy; Jibril A Jibril; Oleg Eremin
Journal:  J Transl Med       Date:  2013-01-15       Impact factor: 5.531

View more
  12 in total

1.  A dual vaccine against influenza & Alzheimer's disease failed to enhance anti-β-amyloid antibody responses in mice with pre-existing virus specific memory.

Authors:  Hayk Davtyan; Anahit Ghochikyan; Armine Hovakimyan; Arpine Davtyan; Richard Cadagan; Annette M Marleau; Randy A Albrecht; Adolfo García-Sastre; Michael G Agadjanyan
Journal:  J Neuroimmunol       Date:  2014-10-16       Impact factor: 3.478

2.  Tumor Resection Recruits Effector T Cells and Boosts Therapeutic Efficacy of Encapsulated Stem Cells Expressing IFNβ in Glioblastomas.

Authors:  Sung Hugh Choi; Daniel W Stuckey; Sara Pignatta; Clemens Reinshagen; Jasneet Kaur Khalsa; Nicolaas Roozendaal; Jordi Martinez-Quintanilla; Kaoru Tamura; Erhan Keles; Khalid Shah
Journal:  Clin Cancer Res       Date:  2017-09-14       Impact factor: 12.531

3.  Natural killer T cell activation overcomes immunosuppression to enhance clearance of postsurgical breast cancer metastasis in mice.

Authors:  Simon Gebremeskel; Daniel R Clattenburg; Drew Slauenwhite; Lynnea Lobert; Brent Johnston
Journal:  Oncoimmunology       Date:  2015-01-22       Impact factor: 8.110

4.  Long-chain omega-3 polyunsaturated fatty acids decrease mammary tumor growth, multiorgan metastasis and enhance survival.

Authors:  Saraswoti Khadge; Geoffrey M Thiele; John Graham Sharp; Timothy R McGuire; Lynell W Klassen; Paul N Black; Concetta C DiRusso; Leah Cook; James E Talmadge
Journal:  Clin Exp Metastasis       Date:  2018-10-16       Impact factor: 5.150

5.  Systemic dysfunction and plasticity of the immune macroenvironment in cancer models.

Authors:  Breanna M Allen; Kamir J Hiam; Cassandra E Burnett; Anthony Venida; Rachel DeBarge; Iliana Tenvooren; Diana M Marquez; Nam Woo Cho; Yaron Carmi; Matthew H Spitzer
Journal:  Nat Med       Date:  2020-05-25       Impact factor: 53.440

6.  Targeting TLR-4 with a novel pharmaceutical grade plant derived agonist, Immunomax®, as a therapeutic strategy for metastatic breast cancer.

Authors:  Anahit Ghochikyan; Alexey Pichugin; Alexander Bagaev; Arpine Davtyan; Armine Hovakimyan; Amir Tukhvatulin; Hayk Davtyan; Dmitry Shcheblyakov; Denis Logunov; Marina Chulkina; Anastasia Savilova; Dmitry Trofimov; Edward L Nelson; Michael G Agadjanyan; Ravshan I Ataullakhanov
Journal:  J Transl Med       Date:  2014-11-29       Impact factor: 5.531

7.  Bone marrow produces sufficient alloreactive natural killer (NK) cells in vivo to cure mice from subcutaneously and intravascularly injected 4T1 breast cancer.

Authors:  Michel van Gelder; Ariane Vanclée; Catharina H M J van Elssen; Pierre Hupperets; Lotte Wieten; Gerard M Bos
Journal:  Breast Cancer Res Treat       Date:  2016-12-03       Impact factor: 4.872

8.  Luciferase Expression Allows Bioluminescence Imaging But Imposes Limitations on the Orthotopic Mouse (4T1) Model of Breast Cancer.

Authors:  V P Baklaushev; A Kilpeläinen; S Petkov; M A Abakumov; N F Grinenko; G M Yusubalieva; A A Latanova; I L Gubskiy; F G Zabozlaev; E S Starodubova; T O Abakumova; M G Isaguliants; V P Chekhonin
Journal:  Sci Rep       Date:  2017-08-10       Impact factor: 4.379

9.  Phenotypic and transcriptomic characterization of canine myeloid-derived suppressor cells.

Authors:  Michelle R Goulart; Sabina I Hlavaty; Yu-Mei Chang; Gerry Polton; Anneliese Stell; James Perry; Ying Wu; Eshita Sharma; John Broxholme; Avery C Lee; Balazs Szladovits; Mark Turmaine; John Gribben; Dong Xia; Oliver A Garden
Journal:  Sci Rep       Date:  2019-03-05       Impact factor: 4.379

Review 10.  Suppressive role of myeloid-derived suppressor cells (MDSCs) in the microenvironment of breast cancer and targeted immunotherapies.

Authors:  Dawei Shou; Liang Wen; Zhenya Song; Jian Yin; Qiming Sun; Weihua Gong
Journal:  Oncotarget       Date:  2016-09-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.